HBPB-1001 is under clinical development by Huons Global and currently in Phase III for Upper Limb Muscle Spasticity. According to GlobalData, Phase III drugs for Upper Limb Muscle Spasticity have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how HBPB-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HBPB-1001 overview

HBPB-1001 is under development for the treatment of post stroke upper limb spasticity and benign masseteric hypertrophy.

Huons Global overview

Huons Global (Huons) is a pharmaceutical company that provides medical solutions for human health. The company carries out development, manufacture and distribution of pharmaceutical products and medical devices. Its product portfolio includes a wide range of ethical drugs, over the counter drugs, healthcare foods and medical devices. Huons offers its products in various formulations such as capsules, tablets, vials, suspensions, syrup, injections and eye drops. It also offers custom manufacturing services to manufacture a wide variety of pharmaceutical products. It markets its products in the markets of the US, 9Latin America, Asia, Middle East, Africa, and Europe. Huons is headquartered in Seongnam, Gyeonggi, South Korea.

For a complete picture of HBPB-1001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.